Behavioral	behavioral	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
MK-801	mk-801	CHEMICALS	O	OTHERS	I
on	on	O	O	O	O
reserpine-treated	reserpine-treated	O	O	O	O
mice	mice	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
dizocilpine	dizocilpine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
MK-801	mk-801	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
noncompetitive	noncompetitive	O	O	O	O
N-methyl-D-aspartate	n-methyl-d-aspartate	O	O	O	O
(	(	O	O	O	O
NMDA	nmda	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
receptor	receptor	O	O	O	O
antagonist	antagonist	O	O	O	O
,	,	O	O	O	O
were	were	O	O	O	O
studied	studied	O	O	O	O
on	on	O	O	O	O
dopamine-related	dopamine-related	O	O	O	O
behaviors	behaviors	O	O	O	O
induced	induced	O	O	O	O
by	by	O	O	O	O
reserpine	reserpine	CHEMICALS	O	OTHERS	I
treatments	treatments	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
study	study	O	O	O	O
focuses	focuses	O	O	O	O
on	on	O	O	O	O
behavioral	behavioral	O	O	O	O
syndromes	syndromes	O	O	O	O
that	that	O	O	O	O
may	may	O	O	O	O
used	used	O	O	O	O
as	as	O	O	O	O
models	models	O	O	O	O
for	for	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
,	,	O	O	O	O
or	or	O	O	O	O
tardive	tardive	O	DISEASE	OTHERS	I
dyskinesia	dyskinesia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
its	its	O	O	O	O
response	response	O	O	O	O
after	after	O	O	O	O
glutamatergic	glutamatergic	O	O	O	O
blockage	blockage	O	O	O	O
.	.	O	O	O	O

Reserpine	reserpine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
1	1	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
administered	administered	O	O	O	O
once	once	O	O	O	O
every	every	O	O	O	O
other	other	O	O	O	O
day	day	O	O	O	O
for	for	O	O	O	O
4	4	O	O	O	O
days	days	O	O	O	O
,	,	O	O	O	O
produced	produced	O	O	O	O
increases	increases	O	O	O	O
in	in	O	O	O	O
orofacial	orofacial	O	O	OTHERS	I
dyskinesia	dyskinesia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
tongue	tongue	O	O	O	O
protrusion	protrusion	O	O	O	O
and	and	O	O	O	O
vacuous	vacuous	O	O	O	O
chewing	chewing	O	O	O	O
in	in	O	O	O	O
mice	mice	O	O	O	O
,	,	O	O	O	O
which	which	O	O	O	O
are	are	O	O	O	O
signs	signs	O	O	O	O
indicative	indicative	O	O	O	O
of	of	O	O	O	O
tardive	tardive	O	DISEASE	OTHERS	I
dyskinesia	dyskinesia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Reserpine	reserpine	CHEMICALS	O	OTHERS	I
also	also	O	O	O	O
produced	produced	O	O	O	O
tremor	tremor	O	DISEASE	OTHERS	I
and	and	O	O	O	O
catalepsy	catalepsy	O	DISEASE	OTHERS	I
,	,	O	O	O	O
which	which	O	O	O	O
are	are	O	O	O	O
signs	signs	O	O	O	O
suggestive	suggestive	O	O	O	O
of	of	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

MK-801	mk-801	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
0.1	0.1	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
administered	administered	O	O	O	O
30	30	O	O	O	O
min	min	O	O	O	O
before	before	O	O	O	O
the	the	O	O	O	O
observation	observation	O	O	O	O
test	test	O	O	O	O
,	,	O	O	O	O
prevented	prevented	O	O	O	O
the	the	O	O	O	O
vacuous	vacuous	O	O	O	O
chewing	chewing	O	O	O	O
movements	movements	O	O	O	O
,	,	O	O	O	O
tongue	tongue	O	O	O	O
protrusions	protrusions	O	O	O	O
and	and	O	O	O	O
catalepsy	catalepsy	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
by	by	O	O	O	O
reserpine	reserpine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
MK-801	mk-801	CHEMICALS	O	OTHERS	I
injection	injection	O	O	O	O
produced	produced	O	O	O	O
a	a	O	O	O	O
significant	significant	O	O	O	O
increase	increase	O	O	O	O
of	of	O	O	O	O
tremor	tremor	O	DISEASE	OTHERS	I
in	in	O	O	O	O
reserpine-treated	reserpine-treated	O	O	O	O
mice	mice	O	O	O	O
.	.	O	O	O	O

Reserpine	reserpine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
1	1	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
administered	administered	O	O	O	O
90	90	O	O	O	O
min	min	O	O	O	O
before	before	O	O	O	O
the	the	O	O	O	O
test	test	O	O	O	O
and	and	O	O	O	O
followed	followed	O	O	O	O
by	by	O	O	O	O
apomophine	apomophine	O	O	OTHERS	I
injection	injection	O	O	O	O
(	(	O	O	O	O
0.1	0.1	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
5	5	O	O	O	O
min	min	O	O	O	O
before	before	O	O	O	O
the	the	O	O	O	O
test	test	O	O	O	O
,	,	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
produce	produce	O	O	O	O
oral	oral	O	O	OTHERS	I
dyskinesia	dyskinesia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
mice	mice	O	O	O	O
.	.	O	O	O	O

On	on	O	O	O	O
the	the	O	O	O	O
other	other	O	O	O	O
hand	hand	O	O	O	O
,	,	O	O	O	O
reserpine	reserpine	CHEMICALS	O	OTHERS	I
induced	induced	O	O	O	O
increases	increases	O	O	O	O
in	in	O	O	O	O
tremor	tremor	O	DISEASE	OTHERS	I
and	and	O	O	O	O
catalepsy	catalepsy	O	DISEASE	OTHERS	I
compared	compared	O	O	O	O
to	to	O	O	O	O
control	control	O	O	O	O
mice	mice	O	O	O	O
.	.	O	O	O	O

MK-801	mk-801	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
0.1	0.1	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
administration	administration	O	O	O	O
attenuated	attenuated	O	O	O	O
the	the	O	O	O	O
catalepsy	catalepsy	O	DISEASE	OTHERS	I
and	and	O	O	O	O
tremor	tremor	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
by	by	O	O	O	O
reserpine	reserpine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Pretreatment	pretreatment	O	O	O	O
with	with	O	O	O	O
reserpine	reserpine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
1	1	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
24	24	O	O	O	O
h	h	CHEMICALS	O	OTHERS	I
before	before	O	O	O	O
the	the	O	O	O	O
observation	observation	O	O	O	O
test	test	O	O	O	O
produced	produced	O	O	O	O
increases	increases	O	O	O	O
in	in	O	O	O	O
vacuous	vacuous	O	O	O	O
chewing	chewing	O	O	O	O
movements	movements	O	O	O	O
and	and	O	O	O	O
tongue	tongue	O	O	O	O
protrusion	protrusion	O	O	O	O
,	,	O	O	O	O
as	as	O	O	O	O
well	well	O	O	O	O
as	as	O	O	O	O
increases	increases	O	O	O	O
in	in	O	O	O	O
tremor	tremor	O	DISEASE	OTHERS	I
and	and	O	O	O	O
catalepsy	catalepsy	O	DISEASE	OTHERS	I
,	,	O	O	O	O
whereas	whereas	O	O	O	O
MK-801	mk-801	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
0.1	0.1	O	O	O	O
mg/kg	mg/kg	O	O	O	O
)	)	O	O	O	O
injection	injection	O	O	O	O
90	90	O	O	O	O
min	min	O	O	O	O
before	before	O	O	O	O
the	the	O	O	O	O
test	test	O	O	O	O
reversed	reversed	O	O	O	O
the	the	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
reserpine	reserpine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

These	these	O	O	O	O
results	results	O	O	O	O
show	show	O	O	O	O
that	that	O	O	O	O
reserpine	reserpine	CHEMICALS	O	OTHERS	I
produces	produces	O	O	O	O
different	different	O	O	O	O
and	and	O	O	O	O
abnormal	abnormal	O	O	OTHERS	I
movements	movements	O	O	OTHERS	I
,	,	O	O	O	O
which	which	O	O	O	O
are	are	O	O	O	O
related	related	O	O	O	O
to	to	O	O	O	O
dose	dose	O	O	O	O
and	and	O	O	O	O
schedule	schedule	O	O	O	O
employed	employed	O	O	O	O
and	and	O	O	O	O
can	can	O	O	O	O
be	be	O	O	O	O
considered	considered	O	O	O	O
as	as	O	O	O	O
parkinsonian-like	parkinsonian-like	O	O	O	O
and	and	O	O	O	O
tardive	tardive	O	O	OTHERS	I
dsykinesia	dsykinesia	O	O	OTHERS	I
signs	signs	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
glutamatergic	glutamatergic	O	O	O	O
blockage	blockage	O	O	O	O
produced	produced	O	O	O	O
by	by	O	O	O	O
NMDA	nmda	CHEMICALS	O	OTHERS	I
can	can	O	O	O	O
restore	restore	O	O	O	O
these	these	O	O	O	O
signs	signs	O	O	O	O
,	,	O	O	O	O
such	such	O	O	O	O
as	as	O	O	O	O
vacuous	vacuous	O	O	O	O
chewing	chewing	O	O	O	O
movements	movements	O	O	O	O
,	,	O	O	O	O
tongue	tongue	O	O	O	O
protrusions	protrusions	O	O	O	O
,	,	O	O	O	O
catalepsy	catalepsy	O	DISEASE	OTHERS	I
and	and	O	O	O	O
tremor	tremor	O	DISEASE	OTHERS	I
according	according	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
employed	employed	O	O	O	O
model	model	O	O	O	O
.	.	O	O	O	O

